EUVIMEDEUVIMED entdecken
Crossref

Metastasis-Directed Stereotactic Body Radiation Therapy in Oligometastatic and Oligoprogressive Solid Malignancy: Outcomes and Effect on Systemic Treatment

Abdulla Alzibdeh iD, Lina Wahbeh, Shatha Abu Taha, Mohamed Qambar, Abdelatif Al Mousa, Jamal Khader, Fawzi Abuhijla iD, Ayah Erjan iD, Anoud Alnsour, Issa Mohamad iD, Baha Sharaf iD, Soha Ahmed und 3 weitere

JCO Global Oncology · 2025-10 · (11)

DOI: 10.1200/go-25-00004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025-10. Verfasst von Abdulla Alzibdeh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan. Hauptthemen laut MEDLINE: Radiosurgery, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To assess the clinical outcomes and evaluate Freedom from Introduction or Switching of Systemic Treatment (FISST) in patients with oligometastatic (OM) and oligoprogressive (OP) disease undergoing stereotactic body radiotherapy (SBRT). METHODS The primary end points were FISST and local control (LC) rates of lesions that received SBRT. The secondary end point was overall survival (OS) after SBRT. To calculate FISST, event was defined as the need to introduce or switch the systemic line of treatment for any reason or inability to provide systemic treatment when needed because of poor performance status (PS) (Eastern Cooperative Oncology Group PS ≥3) or other reasons. OS was a secondary outcome. RESULTS A total of 200 patients were included. The median age was 60 (IQR, 49-70) years. The most common primary tumors were colorectal (61, 30.5%), breast (30, 15.0%), lung (28, 14.0%), head and neck (23, 11.5%), and prostate (16, 8.0%). A total of 257 metastatic lesions were treated. Bone was the most frequent site (115, 44.7%), followed by the liver (55, 21.4%), lung (44, 17.1%), lymph nodes (25, 9.7%), and adrenal glands (11, 4.3%). The median follow-up was 15 months. FISST at 1 and 2 years were 52% and 39%, respectively. LC at 1 and 2 years were 86.3% and 80%, respectively. OS at 1 and 2 years were 76.5% and 64.8%, respectively. Grade III toxicity was reported in 1.5% of patients overall, with no observed grade IV or V toxicity. CONCLUSION SBRT is effective and safe for treating OM and OP solid cancers, prolonging FISST and potentially delaying systemic treatments, particularly in settings with limited access to advanced therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryNeoplasmsHumansMiddle AgedFemaleMaleAgedNeoplasm MetastasisTreatment OutcomeRetrospective StudiesDisease Progression

Autor:innen und Institutionen

  • Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
  • Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
  • Department of Clinical Oncology, Faculty of Medicine, Suez University, Suez, Egypt.

ORCID-Profile: Abdulla Alzibdeh, Fawzi Abuhijla, Ayah Erjan, Issa Mohamad, Baha Sharaf, Sara Mheid, Hikmat Abdel-Razeq, Wafa Asha

Zitieren

APA

Alzibdeh, A., Wahbeh, L., Taha, S. A., Qambar, M., Al Mousa, A., Khader, J., Abuhijla, F., Erjan, A., Alnsour, A., Mohamad, I., Sharaf, B., Ahmed, S., Mheid, S., Abdel-Razeq, H., & Asha, W. (2025). Metastasis-Directed Stereotactic Body Radiation Therapy in Oligometastatic and Oligoprogressive Solid Malignancy: Outcomes and Effect on Systemic Treatment. JCO Global Oncology. https://doi.org/10.1200/go-25-00004

Vancouver

Alzibdeh A, Wahbeh L, Taha SA, Qambar M, Al Mousa A, Khader J, et al. Metastasis-Directed Stereotactic Body Radiation Therapy in Oligometastatic and Oligoprogressive Solid Malignancy: Outcomes and Effect on Systemic Treatment. JCO Global Oncology. 2025. doi:10.1200/go-25-00004

BibTeX
@article{Alzibdeh2025,
  author = {Alzibdeh, Abdulla and Wahbeh, Lina and Taha, Shatha Abu and Qambar, Mohamed and Al Mousa, Abdelatif and Khader, Jamal and Abuhijla, Fawzi and Erjan, Ayah and Alnsour, Anoud and Mohamad, Issa and Sharaf, Baha and Ahmed, Soha and Mheid, Sara and Abdel-Razeq, Hikmat and Asha, Wafa},
  title = {Metastasis-Directed Stereotactic Body Radiation Therapy in Oligometastatic and Oligoprogressive Solid Malignancy: Outcomes and Effect on Systemic Treatment},
  journal = {JCO Global Oncology},
  year = {2025},
  number = {11},
  doi = {10.1200/go-25-00004}
}
Kostenlos starten →